prednisolone has been researched along with Weight Gain in 26 studies
Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.
prednisolone : A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone.
Weight Gain: Increase in BODY WEIGHT over existing weight.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this study was to evaluate the efficacy of rolipram, a phosphodiesterase (PDE) 4 inhibitor, in a mouse model of dermatitis induced by repeated application of 2,4,6-trinitro-1-chlorobenzene (TNCB)." | 7.73 | Effect of orally administered rolipram, a phosphodiesterase 4 inhibitor, on a mouse model of the dermatitis caused by 2,4,6-trinitro-1-chlorobenzene (TNCB)-repeated application. ( Harada, D; Manabe, H; Takashima, Y; Tsukumo, Y, 2006) |
| " Ciclesonide, potently and prednisolone, less effectively, also repressed femoral bone growth (by 41% and 18% at 10 mg/kg), significantly reducing body weight gain (both by 100% at 10 mg/kg), and serum concentrations of acid phosphatase (ACP) and tartarate resistant acid phosphatase (TRACP) (by >30% at 10 mg/kg); both increased serum glucose and triglycerides levels." | 3.81 | Relative potencies of three glucocorticoids to induce hypoplasia of the physis and concomitant biochemical alterations in the rat. ( Bošnjak, B; Brajša, K; Ferenčić, Ž; Glojnarić, I; Hrvačić, B; Marković, S; Šitum, K; Đurić, K, 2015) |
| "The purpose of this study was to evaluate the efficacy of rolipram, a phosphodiesterase (PDE) 4 inhibitor, in a mouse model of dermatitis induced by repeated application of 2,4,6-trinitro-1-chlorobenzene (TNCB)." | 3.73 | Effect of orally administered rolipram, a phosphodiesterase 4 inhibitor, on a mouse model of the dermatitis caused by 2,4,6-trinitro-1-chlorobenzene (TNCB)-repeated application. ( Harada, D; Manabe, H; Takashima, Y; Tsukumo, Y, 2006) |
| " In the croton oil-induced ear edema assay, the topical antiinflammatory activity of 13a was higher than that of its epimer 13b." | 3.69 | Synthesis of 6-(methoxycarbonyl)prednisolone and its derivatives as new antiinflammatory steroidal antedrugs. ( Heiman, AS; Hong, D; Kwon, T; Lee, HL, 1994) |
| "Excessive weight gain is a potential risk." | 1.51 | Twice-weekly glucocorticosteroids in infants and young boys with Duchenne muscular dystrophy. ( Alfano, LN; Anand, P; Connolly, AM; Cradock, MM; Finkel, RS; Flanigan, KM; Florence, JM; Golumbek, PT; Iannaccone, ST; Johnson, LB; Kuntz, NL; Lowes, LP; McDonald, CM; Mendell, JR; Nelson, LL; Nicorici, A; Siener, CA; Zaidman, CM, 2019) |
| "Prednisolone therapy was tapered over several months." | 1.39 | [Woman with type 1 diabetes mellitus and rapidly progressive edema]. ( Dietrich, JW; Ehren, M, 2013) |
| " BMI, weight, and height Z score trajectories were described according to GC starting dosage in prednisone equivalents: high (≥1." | 1.39 | Glucocorticoid-related changes in body mass index among children and adolescents with rheumatic diseases. ( Alos, N; Atkinson, SA; Brant, R; Cabral, DA; Collet, JP; Couch, R; Cummings, EA; Dent, PB; Ellsworth, J; Guzman, J; Hay, J; Houghton, K; Huber, AM; Jurencak, R; Lang, B; Larche, M; Leblanc, C; Miettunen, P; Rauch, F; Rodd, C; Roth, J; Saint-Cyr, C; Scuccimarri, R; Shiff, NJ; Stein, R; Stephure, D; Taback, S; Ward, LM, 2013) |
| "Prednisolone treatment, by contrast, resulted in decreased BW, decreased feed efficiency, increased FHS index, and elevated blood lipid levels." | 1.38 | Effects of high fat diets or prednisolone treatment on femoral head separation in chickens. ( Clark, FD; Coon, CC; Durairaj, V; Huff, GR; Huff, WE; Okimoto, R; Rath, NC, 2012) |
| "The methods used in treatment of osteoporosis induced by glucocorticosteroids are not effective enough." | 1.38 | Effects of thalidomide on the development of bone damage caused by prednisolone in rats. ( Kaczmarczyk-Sedlak, I; Rotko, K; Sedlak, L; Zych, M, 2012) |
| " However, the effects of a low maintenance dosage of corticosteroids on BW have not been studied longitudinally in RTx patients." | 1.32 | Weight changes after renal transplantation: a comparison between patients on 5-mg maintenance steroid therapy and those on steroid-free immunosuppressive therapy. ( Christiaans, MH; Kooman, JP; Nieman, FH; van den Ham, EC; van Hooff, JP, 2003) |
| "Although pemphigus is a well-characterized entity, detailed epidemiologic studies from the Arabian Peninsula are not available." | 1.30 | Pemphigus in Kuwait. ( Al-Baghli, NM; Alsaleh, QA; Dvorak, R; Nanda, A, 1999) |
| "3 mg/kg body weight) initially for 2 months; the dosage was then reduced to half of the initial dose for the third month and was halved again for the fourth and final month." | 1.30 | The efficacy of low-dose oral corticosteroids in the treatment of vitiligo patients. ( Hann, SK; Kim, SM; Lee, HS, 1999) |
| " Twelve potential risk factors were evaluated as covariates: recipient age, body weight after 6 months, body weight gain over 6 months, body mass index after 6 months, body mass index gain over 6 months, current cyclosporine dosage, trough level of cyclosporine in whole blood according to high-performance liquid chromatography after 6 months, cumulative cyclosporine dosage over 6 months, serum bilirubin, type of original cardiac disease, maintenance steroids, and steroid bolus treatment." | 1.28 | The determinants of elevated total plasma cholesterol levels in cardiac transplant recipients administered low dose cyclosporine for immunosuppression. ( Grablowitz, V; Heinz, G; Laczkovics, A; Laufer, G; Miholic, J; Schreiner, W; Wolfram, J; Wollenek, G; Wolner, E, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.85) | 18.7374 |
| 1990's | 12 (46.15) | 18.2507 |
| 2000's | 5 (19.23) | 29.6817 |
| 2010's | 8 (30.77) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Connolly, AM | 1 |
| Zaidman, CM | 1 |
| Golumbek, PT | 1 |
| Cradock, MM | 1 |
| Flanigan, KM | 1 |
| Kuntz, NL | 1 |
| Finkel, RS | 1 |
| McDonald, CM | 1 |
| Iannaccone, ST | 1 |
| Anand, P | 1 |
| Siener, CA | 1 |
| Florence, JM | 1 |
| Lowes, LP | 1 |
| Alfano, LN | 1 |
| Johnson, LB | 1 |
| Nicorici, A | 1 |
| Nelson, LL | 1 |
| Mendell, JR | 1 |
| Ehren, M | 1 |
| Dietrich, JW | 1 |
| Hrvačić, B | 1 |
| Šitum, K | 1 |
| Đurić, K | 1 |
| Bošnjak, B | 1 |
| Ferenčić, Ž | 1 |
| Brajša, K | 1 |
| Marković, S | 1 |
| Glojnarić, I | 1 |
| Sakiyama, T | 1 |
| Shimizu, T | 1 |
| Funakoshi, T | 1 |
| Saito, M | 1 |
| Andrade, Wde C | 1 |
| Tannuri, U | 1 |
| da Silva, LF | 1 |
| Alves, VA | 1 |
| Durairaj, V | 1 |
| Clark, FD | 1 |
| Coon, CC | 1 |
| Huff, WE | 1 |
| Okimoto, R | 1 |
| Huff, GR | 1 |
| Rath, NC | 1 |
| Kaczmarczyk-Sedlak, I | 1 |
| Zych, M | 1 |
| Rotko, K | 1 |
| Sedlak, L | 1 |
| Shiff, NJ | 1 |
| Brant, R | 1 |
| Guzman, J | 1 |
| Cabral, DA | 1 |
| Huber, AM | 1 |
| Miettunen, P | 1 |
| Roth, J | 1 |
| Scuccimarri, R | 1 |
| Alos, N | 1 |
| Atkinson, SA | 1 |
| Collet, JP | 1 |
| Couch, R | 1 |
| Cummings, EA | 1 |
| Dent, PB | 1 |
| Ellsworth, J | 1 |
| Hay, J | 1 |
| Houghton, K | 1 |
| Jurencak, R | 1 |
| Lang, B | 1 |
| Larche, M | 1 |
| Leblanc, C | 1 |
| Rodd, C | 1 |
| Saint-Cyr, C | 1 |
| Stein, R | 1 |
| Stephure, D | 1 |
| Taback, S | 1 |
| Rauch, F | 1 |
| Ward, LM | 1 |
| Uddén, J | 1 |
| Björntorp, P | 1 |
| Arner, P | 1 |
| Barkeling, B | 1 |
| Meurling, L | 1 |
| Rössner, S | 1 |
| van den Ham, EC | 1 |
| Kooman, JP | 1 |
| Christiaans, MH | 1 |
| Nieman, FH | 1 |
| van Hooff, JP | 1 |
| Obeid, OA | 1 |
| Boukarim, LK | 1 |
| Al Awar, RM | 1 |
| Hwalla, N | 1 |
| Harada, D | 1 |
| Tsukumo, Y | 1 |
| Takashima, Y | 1 |
| Manabe, H | 1 |
| Hong, D | 1 |
| Heiman, AS | 1 |
| Kwon, T | 1 |
| Lee, HL | 1 |
| Weisdorf, D | 1 |
| Filipovich, A | 1 |
| McGlave, P | 1 |
| Ramsay, N | 1 |
| Kersey, J | 1 |
| Miller, W | 1 |
| Blazar, B | 1 |
| Giralt, M | 1 |
| Blanquez, A | 1 |
| Avila, J | 1 |
| Hidalgo, J | 1 |
| Sato, K | 1 |
| Satomi, S | 1 |
| Oguma, S | 1 |
| Ohkohchi, N | 1 |
| Okazaki, H | 1 |
| Taguchi, Y | 1 |
| Mori, S | 1 |
| Taylor, R | 1 |
| Kanno, K | 1 |
| Okumura, F | 1 |
| Toriumi, W | 1 |
| Ishiyama, N | 1 |
| Nishiyama, S | 1 |
| Naito, K | 1 |
| Stirling, CM | 1 |
| Boulton-Jones, JM | 1 |
| Simpson, K | 1 |
| Reilly, JJ | 1 |
| Ventham, JC | 1 |
| Ralston, JM | 1 |
| Donaldson, M | 1 |
| Gibson, B | 1 |
| Alsaleh, QA | 1 |
| Nanda, A | 1 |
| Al-Baghli, NM | 1 |
| Dvorak, R | 1 |
| Kim, SM | 1 |
| Lee, HS | 1 |
| Hann, SK | 1 |
| Laufer, G | 1 |
| Grablowitz, V | 1 |
| Laczkovics, A | 1 |
| Miholic, J | 1 |
| Heinz, G | 1 |
| Wollenek, G | 1 |
| Schreiner, W | 1 |
| Wolfram, J | 1 |
| Wolner, E | 1 |
| Yoshimura, A | 1 |
| Ideura, T | 1 |
| Iwasaki, S | 1 |
| Taira, T | 1 |
| Koshikawa, S | 1 |
| Kyle, V | 1 |
| Hazleman, BL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 2 Historically Controlled Trial of Corticosteroids in Young Boys With Duchenne Muscular Dystrophy[NCT02167217] | Phase 2 | 25 participants (Actual) | Interventional | 2014-04-17 | Completed | ||
| A Phase II Trial of Pentoxifylline in Newly-Diagnosed Biliary Atresia[NCT01774487] | Phase 2 | 17 participants (Actual) | Interventional | 2013-02-04 | Terminated (stopped due to Target enrollment was not reached because the medication, pentoxifylline, has a taste that is not well tolerated by infants. The study team decided to end the study before meeting the enrollment goal because of the medication taste.) | ||
| Steroid-Induced Osteoporosis in the Pediatric Population - Canadian Incidence Study (STOPP-CIS)[NCT01663129] | 406 participants (Actual) | Observational | 2005-01-31 | Completed | |||
| ACtive Care After Transplantation, a Lifestyle Intervention in Renal Transplant Recipients[NCT01047410] | 221 participants (Actual) | Interventional | 2010-10-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Bayley III Gross Motor Scaled Score measures motor development. This is normed for typically developing children and follow a bell shaped curve. The scale has mean of 10 +/-3 for children at all ages and is bell shaped. Therefore the two standard deviation range is 16 to 4 with higher values indicated better performance. Lower values have been shown to be common in boys with DMD and it this study the baseline average score was 4.2. (NCT02167217)
Timeframe: One year
| Intervention | units on a scale (Mean) |
|---|---|
| Oral Prednisolone | 4.8 |
The investigators will record the ALT levels at age two years, in patients who had previously been treated with PTX therapy and still have their native liver. Scale 14-45 U/L, with a higher level indicating a worse outcome. (NCT01774487)
Timeframe: 2 years of age
| Intervention | U/L (Mean) |
|---|---|
| Pentoxifylline - Group 1 | 160 |
The investigators will track the weight of patients over the course of therapy in patients receiving 90 days of PTX (this is recorded as part of routine clinical care). The weight will then be compared to standards to calculate a z-score. Normal weight Z-score is greater than or equal to 0, with a higher number of patients meeting this indicating a better outcome. (NCT01774487)
Timeframe: 12 weeks after starting therapy
| Intervention | Participants (Count of Participants) |
|---|---|
| Pentoxifylline - Group 1 | 0 |
| Group 2 | 0 |
The investigators will track the serum conjugated bilirubin (CB) levels over the course of therapy in patients receiving 90 days of PTX (this laboratory test is drawn as part of routine care). Normal CB is 0.0-0.3 mg/dL, with a higher number of patients meeting this indicating a better outcome. (NCT01774487)
Timeframe: 12 weeks after starting therapy
| Intervention | Participants (Count of Participants) |
|---|---|
| Pentoxifylline - Group 1 | 6 |
| Pentoxifylline - Group 2 | 0 |
The investigators will record platelet levels at age two years, in patients who had previously been treated with PTX therapy and still have their native liver. Scale 189-403*10^3 Platelets/μL, with a lower level indicating a worse outcome. (NCT01774487)
Timeframe: 2 years of age
| Intervention | 10^3 Platelets/μL (Mean) |
|---|---|
| Pentoxifylline - Group 1 | 208 |
"The investigators will measure spleen size by ultrasound at 2 years of age, in patients who had received PTX therapy earlier and still have their native liver. Normal spleen size range (10th-90th percentile) at this age is 6.4-8.6 cm, with a value exceeding this range indicating a worse outcome." (NCT01774487)
Timeframe: 2 years of age
| Intervention | cm (Mean) |
|---|---|
| Pentoxifylline - Group 1 | 10.0 |
The investigators will track time to liver transplant. The shorter time to liver transplant indicates a worse outcome. (NCT01774487)
Timeframe: Baseline and up to two years after therapy finishes
| Intervention | days (Mean) |
|---|---|
| Pentoxifylline - Group 1 | 317 |
| Pentoxifylline - Group 2 | 273 |
1 trial available for prednisolone and Weight Gain
| Article | Year |
|---|---|
Combination graft-versus-host disease prophylaxis using immunotoxin (anti-CD5-RTA [Xomazyme-CD5]) plus methotrexate and cyclosporine or prednisone after unrelated donor marrow transplantation.
Topics: Adolescent; Adult; Antibodies, Monoclonal; Bone Marrow; Bone Marrow Transplantation; Child; Child, P | 1993 |
25 other studies available for prednisolone and Weight Gain
| Article | Year |
|---|---|
Twice-weekly glucocorticosteroids in infants and young boys with Duchenne muscular dystrophy.
Topics: Case-Control Studies; Child, Preschool; Cohort Studies; Disease Progression; Glucocorticoids; Humans | 2019 |
Adverse effects of short-course corticosteroids in children.
Topics: Adrenal Cortex Hormones; Aggression; Anxiety; Chickenpox; Child; Dexamethasone; Glucocorticoids; Hum | 2017 |
[Woman with type 1 diabetes mellitus and rapidly progressive edema].
Topics: Anti-Inflammatory Agents; Biopsy; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Diagnosis, Diff | 2013 |
Relative potencies of three glucocorticoids to induce hypoplasia of the physis and concomitant biochemical alterations in the rat.
Topics: Acid Phosphatase; Animals; Beclomethasone; Biomarkers; Bone Development; Dose-Response Relationship, | 2015 |
Case of yellow nail syndrome accompanied by nephrotic syndrome.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Bronchiolitis; Dermis; Fatigue; Glucocorticoids; Huma | 2016 |
Effects of the administration of pentoxifylline and prednisolone on the evolution of portal fibrogenesis secondary to biliary obstruction-an experimental study in growing animals.
Topics: Animals; Biliary Atresia; Biliary Tract Diseases; Cholestasis; Common Bile Duct Diseases; Disease Mo | 2009 |
Effects of high fat diets or prednisolone treatment on femoral head separation in chickens.
Topics: Animal Nutritional Physiological Phenomena; Animals; Body Weight; Bone Diseases; Chickens; Cholester | 2012 |
Effects of thalidomide on the development of bone damage caused by prednisolone in rats.
Topics: Administration, Oral; Animals; Bone Remodeling; Dose-Response Relationship, Drug; Femur; Glucocortic | 2012 |
Glucocorticoid-related changes in body mass index among children and adolescents with rheumatic diseases.
Topics: Adolescent; Body Mass Index; Child; Child, Preschool; Female; Follow-Up Studies; Glucocorticoids; Hu | 2013 |
Effects of glucocorticoids on leptin levels and eating behaviour in women.
Topics: Body Mass Index; Fasting; Feeding Behavior; Female; Glucocorticoids; Humans; Leptin; Middle Aged; Po | 2003 |
Weight changes after renal transplantation: a comparison between patients on 5-mg maintenance steroid therapy and those on steroid-free immunosuppressive therapy.
Topics: Acute Disease; Adult; Age Factors; Cyclosporine; Female; Glucocorticoids; Graft Rejection; Humans; I | 2003 |
Postprandial glycogen and lipid synthesis in prednisolone-treated rats maintained on high-protein diets with varied carbohydrate levels.
Topics: Animals; Dietary Carbohydrates; Dietary Proteins; Eating; Energy Intake; Glucocorticoids; Lipid Meta | 2006 |
Effect of orally administered rolipram, a phosphodiesterase 4 inhibitor, on a mouse model of the dermatitis caused by 2,4,6-trinitro-1-chlorobenzene (TNCB)-repeated application.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Administration, Oral; Animals; Anti-Inflammatory Agents; Cell C | 2006 |
Synthesis of 6-(methoxycarbonyl)prednisolone and its derivatives as new antiinflammatory steroidal antedrugs.
Topics: Administration, Topical; Animals; Anti-Inflammatory Agents; Corticosterone; Croton Oil; Dose-Respons | 1994 |
Effect of superoxide dismutase, allopurinol and glucocorticoids on liver and lung metallothionein induction by endotoxin in the rat.
Topics: Allopurinol; Animals; Cytosol; Escherichia coli; Lipopolysaccharides; Liver; Lung; Male; Metallothio | 1993 |
[Relationship between aseptic necrosis of femoral head bone and immunosuppression therapy, especially CsA administration].
Topics: Adolescent; Adult; Azathioprine; Cyclosporine; Female; Femur Head Necrosis; Humans; Immunosuppressio | 1993 |
Successful management of hyperemesis gravidarum using steroid therapy.
Topics: Adult; Antiemetics; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Hydroco | 1996 |
Nephrotoxic serum-induced nephritis in Wistar-Kyoto rats: a model to evaluate antinephritic agents.
Topics: Animals; Basement Membrane; Body Weight; Cyclophosphamide; Cyclosporine; Disease Models, Animal; Dos | 1998 |
Progressive oedema in a 30-year-old.
Topics: Adult; Anti-Inflammatory Agents; Capillary Leak Syndrome; Capillary Permeability; Edema; Female; Hum | 1998 |
Reduced energy expenditure in preobese children treated for acute lymphoblastic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Child; Energy Metabolism; Fe | 1998 |
Pemphigus in Kuwait.
Topics: Age of Onset; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Cushi | 1999 |
The efficacy of low-dose oral corticosteroids in the treatment of vitiligo patients.
Topics: Abdominal Pain; Acne Vulgaris; Administration, Oral; Adolescent; Adrenal Cortex Hormones; Adult; Age | 1999 |
The determinants of elevated total plasma cholesterol levels in cardiac transplant recipients administered low dose cyclosporine for immunosuppression.
Topics: Adult; Cholesterol; Cyclosporine; Drug Therapy, Combination; Female; Heart Transplantation; Humans; | 1992 |
Aggravation of minimal change nephrotic syndrome by administration of human albumin.
Topics: Adult; Dietary Proteins; Female; Humans; Male; Nephrosis, Lipoid; Prednisolone; Recurrence; Retrospe | 1992 |
Treatment of polymyalgia rheumatica and giant cell arteritis. II. Relation between steroid dose and steroid associated side effects.
Topics: Drug Administration Schedule; Giant Cell Arteritis; Humans; Polymyalgia Rheumatica; Prednisolone; Pr | 1989 |